This trial is evaluating whether XmAb®22841 will improve 1 primary outcome in patients with Melanoma. Measurement will happen over the course of 56 Days.
This trial requires 242 total participants across 2 different treatment groups
This trial involves 2 different treatments. XmAb®22841 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"This was the most common cancer in the United States. The peak incidence for adults ages 20-34 years with this type of lung cancer is expected to be in the future." - Anonymous Online Contributor
"Findings from a recent study provide the first compelling evidence that XMab is not more effective than a placebo for the management of advanced and refractory solid tumours." - Anonymous Online Contributor
"The signs of carcinoma, non-small-cell lung vary according to the organ of origin and metastasis. A positive sign is a symptom or sign that should be evaluated with a careful medical history and physical examination." - Anonymous Online Contributor
"A number of systemic or inhaled therapies have been found to be effective. In addition, certain therapies, such as chemotherapy, may be used to decrease pain in patients with lung cancer. The most effective form of treatment may be determined by a multimodal approach, with different therapies being employed concurrently." - Anonymous Online Contributor
"Chronic or chronic smoking may cause lung carcinoma, and is more likely than the age-adjusted rate in men born before the turn of the 20th century. Smoking decreases lung carcinoma risk in women, presumably by a shared defect in the proliferative potential of the normal epithelium. Larger studies may help in determining the role and mechanisms of genetic susceptibility in lung carcinoma." - Anonymous Online Contributor
"The overall and racial/ethnic differences in lung cancer incidence suggest that current screening practices in the United States are suboptimal at detecting lung malignancies in the general population and that future screening recommendations should target high-risk subgroups such as people who are current smokers and/or African-Americans." - Anonymous Online Contributor
"No patients who received a curative surgical resection were known to have been alive at 30 months after surgery. When local recurrence or distant metastasis occurred in the curative group, the median survival time was 17 months postoperatively, while in the operative secondarily group, the median survival time was 36 months postoperatively." - Anonymous Online Contributor
"Itching, dry skin, increased lacrimation, headache, fever and weight gain are very common side effects of Xmab™ 22841. They may occur during treatment or for weeks or months after treatment. All these side effects are mild and easily manageable, thus Xmab™ 22841 causes no more side effects than placebo, when used for indications as listed in the clinical trials. Symptoms and signs can be mild or moderate in many indications such as advanced squamous cell carcinoma of the prostate, renal renal cell carcinoma and metastatic melanoma or sarcoma of unknown primary origin." - Anonymous Online Contributor
"Primary pulmonary malignancy could be caused by external factors, as we found that the group of patients with a history of previous pulmonary malignancy was on average younger than the group without such a history; the same applies to the group of smokers. Recent findings suggest the absence of an important role for environmental factors in the development of lung malignancies. A prospective study is needed to assess the association between environmental smoking history and lung cancer development." - Anonymous Online Contributor
"Lung carcinomas are rare in younger patients. Larger-scale studies are required to determine the age at onset to allow more optimal staging and early detection." - Anonymous Online Contributor
"We show that Xmab22841 is effective in eradicating XMRV in human prostate cancer tissue and tumor-derived cell cultures. XMRV may be an etiologic agent in prostate cancer or it may not. We therefore propose to test to the presence of an XMRV infection in patients with prostate cancer using Xmab22841 so that XMRV can be identified as either a benign or a pathogenic agent." - Anonymous Online Contributor
"In the last quarter of the twentieth century, the use of XMab is increasing in the USA. The treatment of metastatic and locally advanced NSCLC with XMab is safe." - Anonymous Online Contributor